Global Chronic Migraine Treatment Market: Introduction
Migraine is a painful episodic disorder that sometimes develops into a chronic form. It is one of the most prevalent neurological conditions in clinical practice. Chronic migraine (CM) is the natural development of migraine in its chronic form and has a headache frequency of 15 days per month with similar characteristics to migraine assaults. Many patients with chronic migraine also have overuse of medication, described as at least 10 days per month using a compound analgesic, opioid, triptan, or ergot derivative.
Global Chronic Migraine Treatment Market: Competitive Landscape
Founded in 1996, Novartis AG is among the top global pharmaceutical companies operating across all the geographies in almost all the specialties. It was established through the merger of Ciba-Geigy and Sandoz in 1996. It acquired Alcon, Inc. and expanded its base in eye care market. Novartis operates in patented pharmaceutical products, generic pharmaceuticals & biosimilars, and surgical and vision care segments. It offers many OTC as well as generic drugs for acute attack treatment of migraine. The company is investing into specialty prophylactic treatment drugs through its recent acquisitions and strategic collaborations.
Need an Overview of the Report on Chronic Migraine Treatment Market? Ask for the Brochure here
Incorporated in 1849, Pfizer Inc. is one of the leading biopharmaceutical companies. The company manages its commercial operations through two segments: Global Innovative Products and Global Essential Health. The global innovative products segment includes pharmaceutical sub-segment that focuses on novel pharmaceutical products, vaccines, oncology products, and consumer healthcare. The global essential health segment includes branded generics, generics, biosimilar, and infusion systems. Pfizer has expanded its neurosciences product portfolio through indigenous product developments and acquisitions across the market. The company offers OTC and prescription drugs for migraine treatment in the form of tablets as well as other forms.
Other key players operating in the global chronic migraine treatment market include AstraZeneca Plc., Allergan Plc., GlaxoSmithKline Plc., Eli Lilly & Company, Merck & Co., Inc., Janssen Pharmaceutical Company (Johnson & Johnson), Endo Pharmaceutical Inc., Zosano Pharma Corporation, Alder BioPharmaceutical, Inc., Eisai Co., Ltd., and Avanir Pharmaceuticals, Inc.
Global Chronic Migraine Treatment Market: Dynamics
High Prevalence of Migraine and Increasing Transition from Episodic to Chronic Migraine to Drive the Market
According to a report by the World Health Organization (WHO), in 2013, migraine was the 6th most common cause for a year lost due to disability across the globe. According to a study, titled “Lifting the Burden”, conducted by World Health Organization and other prominent institutes in 2011, the prevalence of migraine across the globe was around 11.0%. Other independent studies suggest this prevalence to be around 14.7%. Prevalence of migraine among females is supposed to be 2 to 3 times more than in men. According to The Migraine Trust of the U.K., around 2% of the world population is estimated to be affected by chronic migraine. Furthermore, it is estimated that around 2 to 3% of episodic migraine patients transitioned to chronic migraine patients. Migraine attacks are triggered by various factors such as environmental change, hormonal imbalance, and dietary change. Rise in incidences of these triggering factors is projected to increase the number of episodic migraine patients, which in turn, is likely to increase chronic migraine patients’ population.
Stuck in a Neck-to-Neck Competition with other Brands? Request a Custom Report on “Chronic Migraine Treatment Market” here
Ongoing Investment in Alternative Therapies to Restrain the Market
Various complementary alternative therapies are being practiced for chronic migraine treatment such as manual therapy, chiropractic, homeopathy, and Ayurveda. It is estimated that emerging and under-developed markets prominently use complementary alternative therapies for migraine treatment. According to a study conducted by physicians and scientists of Harvard Medical School of Boston, Massachusetts, U.S. in 2011, around 4.5% of adults in the U.S. relied on complementary alternative therapies to relieve migraine. Key industry players and research institutes are investing into development of new portable neuro-stimulating devices to offer abortive as well prophylactic treatment of migraine. Recent FDA approvals for such devices are projected to attract new players in this market. A few examples of such devices include sTMS mini by eNeuro, and Cefaly by Roxon.
Global Chronic Migraine Treatment Market: Segmentation
The global chronic migraine treatment market can be segmented based on:
- Route of Administration
- Distribution Channel
Global Chronic Migraine Treatment Market, by Treatment
In terms of treatment, the global chronic migraine treatment market can be divided into:
- Abortive Treatment
- Ergot Alkaloids
- Prophylactic Treatment
- Botulinum Toxin
Global Chronic Migraine Treatment Market, by Route of Administration
Based on route of administration, the global chronic migraine treatment market can be classified into:
- Others (Nasal Spray, Transdermal Patch, suppositories)
Global Chronic Migraine Treatment Market, by Distribution Channel
In terms of distribution channel, the global chronic migraine treatment market can be segregated into:
- Hospitals Pharmacies
- Retail Pharmacies
- Others (Online Pharmacies, Drug Stores)
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.